Related Experiment Videos
The influence of a new antiarrhythmic drug, Craviten (M-71) on coronary flow
Polish Journal of Pharmacology and Pharmacy
|November 1, 1980
Insights
Craviten (M-71) enhances coronary blood flow but temporarily reduces heart contraction rate and force in cats. Its short-lived effects suggest potential use for acute cardiac insufficiency with pain or arrhythmia.
Area of Science:
- Cardiovascular pharmacology
- Cardiac electrophysiology
Background:
- Acute cardiac insufficiency presents significant clinical challenges.
- Managing cardiac pain and arrhythmia requires effective therapeutic agents.
Purpose of the Study:
- To investigate the cardiovascular effects of Craviten (M-71).
- To evaluate the potential therapeutic applications of Craviten in cardiac conditions.
Main Methods:
- In vitro and in situ studies on the cat heart.
- Assessment of coronary blood flow, contraction rate, and contractile force.
Main Results:
- Craviten (M-71) demonstrated increased coronary flow.
- A transient depression in the rate and contractile force of the heart was observed.
- The drug's effects were found to be short-lasting.
Conclusions:
- Craviten (M-71) exhibits a unique profile of increasing coronary flow while temporarily decreasing cardiac contractility.
- Its short duration of action suggests potential utility in managing acute cardiac insufficiency, particularly when associated with pain or arrhythmia.
Abstract:
Craviten (M-71) increases the coronary flow, depresses the rate of contractions, and transiently depresses the contractile force of the cat heart in vitro and in situ. As the action of the drug is short-lasting, its usefulness in treatment of acute cardiac insufficiency accompanied by pain is suggested. It is also potentially useful in cardiac insufficiencies accompanied by arrhythmia.